June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Ocular Hypotensive and Neuroprotective Effects of Agmatine
Author Affiliations & Notes
  • Samin Hong
    Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships Samin Hong, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4938. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Samin Hong; Ocular Hypotensive and Neuroprotective Effects of Agmatine. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4938. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Agmatine, a primary polyamine and putative neuromodulater, is known to have neuroprotective effects on various neuronal damages in the central nervous system. In this investigation, it was assessed whether agmatine effectively lowers the intraocular pressure (IOP) and rescues the injured retinal ganglion cells (RGCs) in a wide range of experimental models..

Methods: Agmatine, a primary polyamine and putative neuromodulater, is known to have neuroprotective effects on various neuronal damages in the central nervous system. In this investigation, it was assessed whether agmatine effectively lowers the intraocular pressure (IOP) and rescues the injured retinal ganglion cells (RGCs) in a wide range of experimental models.

Results: In a chronic ocular hypertensive rat model, IOP was significantly increased (about a 50% increase over the baseline IOP) and well maintained until 12 weeks. Topically administered agmatine powerfully lowered IOP to approximately 30% of its pretreatment level. EVC caused about 55% loss of RGCs in the control group, but agmatine appeared to attenuate this RGC loss to around 20%. Meanwhile, in a transient ocular ischemic mouse model, MCAO induced apoptosis to mostly the whole cells in the entire retinal layer, but topically/systemically administered agmatine significantly reduced the proportion of apoptotic cells.

Conclusions: Agmatine appeared to effectively lower IOP and rescue RGCs in a chronic ocular hypertensive rat model and decreased retinal damage in a transient ocular ischemic mouse model. Although the precise mechanisms underlying these effects have not been well established yet, it is possible that agmatine offers a powerful new ocular hypotensive and neuroprotective agent for patients suffering from glaucoma.

Keywords: 531 ganglion cells • 568 intraocular pressure • 615 neuroprotection  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×